ClinicalTrials.gg
RecruitingNCT06579664Updated Sep 8, 2025

Intermittent Theta Burst Stimulation on Cognitive Impairment of Cerebral Small Vessel Disease

An interventional study of iTBS and sham iTBS in Cerebral Small Vessel Diseases and Cognitive Impairment, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital — 6 open to participants now, 7 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · Beijing Tiantan Hospital.

Started
2025
with 2 others
No phase
Only one
of the 10
Registered
8th of 10
by date

Among the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital, this one is one of 3 that started in 2025, is the only one with no phase, and was the 8th registered.

Cerebral Small Vessel Diseases

128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.

Browse Cerebral Small Vessel Diseases studies →

Open to participants now

6 of the 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cerebral Small Vessel Diseases by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

The cerebral small vessel diseases (CVSD) can cause severe and lasting damage to cognition function while the current available treatment of vascular cognitive impairment (VCI) is limited. The purpose of this study is to explore the feasibility, safety, and efficacy of intermittent Theta Burst Stimulation (iTBS) on cognitive impairment of cerebral small vessel disease.

Read the detailed description

The cerebral small vessel diseases(CSVD) refers to any pathologic process that damages small end arteries, arterioles, venules, and brain capillaries. CVSD can cause severe and lasting damage to cognition function while the current available treatment of vascular cognitive impairment (VCI) is limited. Repetitive transcranial magnetic stimulation, a noninvasive neuromodulation treatment, has been proven effective for various neurological diseases such as depression, Parkinson's disease, poststroke movement disorders, and cognitive impairment. Theta-burst stimulation (TBS) has recently attracted broad attention as a form of accelerated repetitive transcranial magnetic stimulation that is more effective in achieving similar or higher therapeutic effects than conventional repetitive transcranial magnetic stimulation. The intermittent TBS (iTBS) has been considered to enhance cortical excitability. Personalized Brain Function Sector (pBFS) is a method that accurately delineate whole-brain personalized functional networks utilizing resting-state functional magnetic resonance imaging (MRI). The purpose of this study is to explore the efficacy and safety of iTBS under the guidance of pBFS in improving cognitive function in patients with CSVD.

This trial was a randomized, single-center, double-blind, sham-controlled parallel trial. The trial planned to enroll 58 patients with clinical evidence of CVSD and cognitive impairment, aged 45-85 years.

Participants were randomly assigned to receive iTBS stimulation or sham stimulation for 3 weeks in 1:1 ratio.

iTBS group: iTBS stimulation to the left dorsolateral prefrontal cortex (DLPFC), 1800 pulses /session, 4 sessions /day, as well as standard treatment and management according to the related guidelines.

sham iTBS group: mimicked iTBS stimulation at the same stimulation parameters, dose, and duration as the iTBS group with a sham coil, as well as standard treatment and management according to the related guidelines.

Follow up: Face to face interviews will be made on baseline, 15±7 days after randomization and 90±7 days after iTBS intervention.

The score of Montreal Cognitive Assessment Scale (MoCA) 90 days after iTBS intervention will be tested by the t-test or the Wilcoxon rank-sum test. The change of MoCA between baseline and 90 days after iTBS intervention will be tested by the two-sample t-test or the Mann-Whitney U test.

03

Conditions studied

  • Cerebral Small Vessel Diseases
  • Cognitive Impairment

Keywords

  • Cerebral Small Vessel Diseases
  • Cognitive Impairment
  • Intermittent Theta-Burst Stimulation
  • Personalized Brain Function Sector
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 45-80 years old, with no limitation on sex.
  2. Clinical evidence of CVSD as evidenced by one or more of:

    • White matter hyperintensity with Fazekas score ≥2
    • a lacunar stroke syndrome (e.g. pure motor stroke, pure sensory stroke, sensorimotor stroke, ataxic hemiparesis, or clumsy hand dysarthria syndrome) with a corresponding acute lacunar infarct on diffusion weighted imaging (DWl) for cases imaged (clinically) within 3 weeks of stroke or anatomically compatible lacunar infarct on fluid attenuated inversion recovery (FLAIR)/T1 MRI for cases imaged later after stroke (diameter≤1.5cm).
  3. Independence of daily life (modified Rankin Scale score ≤2).
  4. Mild vascular cognitive impairment (memory and/or other cognitive domain abnormalities lasting for at least 3 months) with a score of 10-22.
  5. Routine, consistent medication for 4 weeks or more.

Exclusion criteria

Exclusion Criteria:

  1. History of stroke within previous 30 days, including cerebral infarction (diameter >15mm), cerebral hemorrhage, subarachnoid hemorrhage;
  2. History of cerebral cortex infarction.
  3. History of cerebrovascular malformation or aneurysmal subarachnoid hemorrhage, or discovery of an untreated aneurysm > 3mm.
  4. Carotid or vertebral artery stenosis > 50% measured on North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria.
  5. Possible amyloid cerebrovascular disease with at least 2 lobar hemorrhagic lesions (i.e., intracranial hemorrhage, cerebral microbleeds (CMB), cortical superficial siderosis, or convexal subarachnoid hemorrhage) measured on Boston Criteria 2.0; Or at least one lobar hemorrhagic lesion and at least one white matter feature (severe enlarged perivascular space in the centrum semiovale or multiple punctate white matter hyperintensities) without deep hemorrhagic lesion (cerebral hemorrhage or CMB) on T2* weighted MRI.
  6. Recorded diagnosis of neurodegenerative diseases (e.g. Alzheimer's disease and Parkinson's disease).
  7. Definite non-vasogenic white matter lesions (e.g. multiple sclerosis, cortical dysplasia in adults, metabolic encephalopathy).
  8. Other psychiatric disorders diagnosed measured on the - V (DSM-V) diagnostic criteria; Or apparent suicidal intent.
  9. Unable to tolerate MRI or to MRI (e.g., claustrophobia).
  10. T1 or T2 weighted MRI shows focal brain injury.
  11. Patients or first-degree relatives with a history of seizures.
  12. Implanted pacemakers, vagus nerve stimulators, deep brain stimulators, or other metal medical devices.
  13. Received transcranial magnetic stimulation therapy within previous 3 months.
  14. Severe organic diseases with expected survival time \<5 years, such as malignant tumor.
  15. Women of child bearing potential, pregnant or breastfeeding.
  16. Individual who have difficulty communicating verbally to the extent that they are unable to communicate, understand or follow instructions normally, and are unable to cooperate with treatment and evaluation.
  17. Combined with alcohol and drug abuse history.
  18. Unable to be cooperative and complete the follow-up due to geographical or other reasons.
  19. Participated in other clinical trials.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
58 participants (estimated)

Study arms

  • Active comparator
    iTBS group

    Device: iTBS

  • Sham comparator
    sham iTBS group

    Device: sham iTBS

Interventions

  • DeviceiTBS

    Participants in active group will receive iTBS stimulation in 50-Hz triplets at 5 Hz for 600 seconds per session (2 seconds on and 8 seconds off) at 90% of their resting motor threshold to the left dorsolateral prefrontal cortex (DLPFC).Each intervention day includes 4 sessions (1800 pulses/session) of stimulation delivering a total of 7200 active pulses. This treatment protocol will be conducted 15 consecutive days.

  • Devicesham iTBS

    Participants in the sham group will receive sham iTBS stimulation, which will use the same stimulation parameters, dosage, and duration as the active group, but will employ a sham coil. The sham coil is identical in appearance to the real stimulus coil and simulate the sound of a real stimulus, but do not produce a real stimulus.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Montreal Cognitive Assessment Scale

    Montreal Cognitive Assessment Scale (Beijing Edition) scores from 0 to 30. A higher score indicates better cognitive function.

    Time frame: at 90±7days after iTBS therapy

Secondary outcomes

  1. Change from baseline in Mini-mental State Examination

    Mini-mental State Examination (MMSE) scores from 0 to 30. A higher score indicates better cognitive function.

    Time frame: at 90±7days after iTBS therapy

  2. Change from baseline in verbal fluency test

    Scoring of verbal fluency test (VFT) is based on the number of words produced by the participants from a category in a given time. A higher score indicates better cognitive function.

    Time frame: at 90±7days after iTBS therapy

  3. Change from baseline in trail making test

    Scoring of color trial test (CTT) is based on time taken to complete the test and the number of wrong answers. Shorter the test time and less the mistakes, the better the outcome.

    Time frame: at 90±7days after iTBS therapy

  4. Change from baseline in Stroop Test

    Scoring of Stroop Test is based on time taken to complete the test and the number of wrong answers. Shorter the test time and less the mistakes, the better the outcome.

    Time frame: at 90±7days after iTBS therapy

  5. Change from baseline in digital span test

    Digital span test scores from 0 to 24. A higher score indicates better cognitive function.

    Time frame: at 90±7days after iTBS therapy

  6. Change from baseline in Hamilton Anxiety Scale

    Hamilton Anxiety Scale (HAMA) scores from 0 to 56. A lower score indicates better emotional state.

    Time frame: at 15±7days and 90±7days after iTBS therapy

  7. Change from baseline in Hamilton Depression Scale

    Hamilton Depression Scale (HAMD) scores from 0 to 68. A lower score indicates better emotional state.

    Time frame: at 15±7days and 90±7days after iTBS therapy

  8. Change from baseline in Pittsburgh sleep quality index

    Pittsburgh sleep quality index (PSQI) scores from 0 to 21. A lower score indicates better sleep quality.

    Time frame: at 15±7days and 90±7days after iTBS therapy

  9. Change from baseline in The Short Physical Performance Battery(SPPB)

    SPPB scores from 0 to 12. A higher score indicates better motor ability.

    Time frame: at 15±7days and 90±7days after iTBS therapy

  10. Change from baseline in The 5-level EuroQol five Dimensions Questionnaire

    The 5-level EuroQol five Dimensions Questionnaire (EQ-5D-5L) scores from 0 to 25. A lower score indicates better life quality.

    Time frame: at 15±7days and 90±7days after iTBS therapy

  11. Change from baseline in 6 meter walk test

    Scoring of 6 meter walk test is based on time taken to complete the test. A lower score indicates better motor ability.

    Time frame: at 15±7days and 90±7days after iTBS therapy

  12. Change from baseline in step-by-step walk test

    Step-by-step walk test scores from 0 to 8. A lower score indicates better motor ability.

    Time frame: at 15±7days and 90±7days after iTBS therapy

  13. Change from baseline in 3-dimensional gait analysis (3D-IGA)

    Gait features can be assessed with 3D-IGA providing rhythm, pace, phases, joint angle and other quantitative indicators.

    Time frame: at 15±7days and 90±7days after iTBS therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 30, 2024
StartActual
Mar 24, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579664
Responsible party
yilong Wang (Executive Vice-President, Beijing Tiantan Hospital) — Principal investigator
First posted
Aug 30, 2024
Start date
Mar 24, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 8, 2025

Study contacts

Weiqi Chen
Contact
weiqichen@aliyun.com
010-59975029

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion